Cargando…

P17 Vancomycin therapeutic drug monitoring—a call for change?

OBJECTIVES: Despite the widespread use of vancomycin, optimization of dosing can be difficult. Increased vancomycin concentrations are associated with nephrotoxicity, while subtherapeutic levels may lead to inadequate antibacterial therapy and risk development of antimicrobial resistance. Recent gui...

Descripción completa

Detalles Bibliográficos
Autores principales:	Payne, Lara, Buckingham, Christian J., Wade, Paul, Brown, Aisling F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Posters Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849401/ http://dx.doi.org/10.1093/jacamr/dlac004.016

Ejemplares similares

1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020)

182. Missed Opportunities to Discontinue Unnecessary Vancomycin During Pharmacist Therapeutic Monitoring
por: Medler, Corey J, et al.
Publicado: (2020)

P19 IV antimicrobial duration in practice
por: Akintimehin, Abisoye O., et al.
Publicado: (2022)

250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey
por: Dagenais, R., et al.
Publicado: (2022)

Audit of therapeutic drug monitoring of dosing of vancomycin on an intensive care unit
por: Mason, P, et al.
Publicado: (2002)

1096. Evaluation of Vancomycin Pharmacokinetics in Intravenous Drug Users
por: Weihs, Sayo, et al.
Publicado: (2021)

Pharmacist and physician insight of vancomycin therapeutic drug-monitoring changes
por: Gregory, Eric R., et al.
Publicado: (2022)

1328. Vancomycin exposure and utilization following implementation of an AUC-guided monitoring guideline in children
por: Quraishi, Ruquaya, et al.
Publicado: (2020)

192. The Use of Area Under the Curve to Determine Therapeutic Vancomycin Dosing in Skin and Soft Tissue Infections
por: Dea, Lauren, et al.
Publicado: (2020)

227. Evaluation of Empiric Vancomycin Utilization at 72 Hours Post Admission: is De-escalation of Vancomycin Appropriate?
por: Naderi, Mandana, et al.
Publicado: (2020)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

604. Factors Associated with Adverse Drug Reactions Leading to Discontinuation of Vancomycin in Outpatient Parenteral Antimicrobial Therapy
por: McDonald, Josh, et al.
Publicado: (2020)

175. Assessment of Institutional Uptake of Vancomycin AUC Monitoring One-Year Post Guideline Publication in Hospitals Across the United States
por: Bradley, Nicole, et al.
Publicado: (2021)

1102. Evaluation of Vancomycin Accumulation in Patients with Obesity
por: Assadoon, Maha, et al.
Publicado: (2021)

Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency
por: Abuhasna, Said, et al.
Publicado: (2011)

Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review
por: Ye, Zhi-Kang, et al.
Publicado: (2014)

881. Efficacy of Antibiotic Prophylaxis with Vancomycin in Cardiothoracic Surgery
por: Cooper, Margaret, et al.
Publicado: (2020)

1091. Validation of an Allometrically Scaled Body Weight Equation to Predict Vancomycin Clearance and Guide 24-Hour Vancomycin AUC Dosing in Obese Patients
por: Footer, Brent, et al.
Publicado: (2021)

1090. Does calculation method matter for targeting vancomycin AUC?
por: Chang, Jack, et al.
Publicado: (2021)

1110. In Vivo Pharmacodynamics of Vancomycin Against Staphylococci in Young Infants
por: Gwee, Amanda, et al.
Publicado: (2021)

649. The Clinical Significance of Sequence Type 17 of Vancomycin-Resistant Enterococcus faecium
por: Kim, Si-Ho, et al.
Publicado: (2018)

Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia
por: Luther, Megan, et al.
Publicado: (2017)

63. PK-RNN-V: A Deep Learning Model for Vancomycin Therapeutic Drug Monitoring using Electronic Health Record Data
por: Masayuki, Nigo, et al.
Publicado: (2021)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Implementation of a Vancomycin AUC Monitoring Program: Peaks and Pitfalls
por: Kassamali, Zahra, et al.
Publicado: (2017)

Vancomycin Safety Monitoring Using an Electronic Health Record Database
por: Veve, Michael P, et al.
Publicado: (2017)

1354. Reducing vancomycin utilization rate in a level 4 NICU
por: Chang, Millie R, et al.
Publicado: (2020)

1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021)

1097. A Comparison of Area-Under Curve (AUC)-Guided vs Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-analysis
por: Lim, Ashley Shiyuan, et al.
Publicado: (2021)

Experience of Vancomycin Therapeutic Drug Monitoring in Two Multidisciplinary Hospitals in Latvia
por: Mauliņa, Inga, et al.
Publicado: (2022)

Vancomycin prescribing and therapeutic drug monitoring: Challenges of real clinical practice
por: Abdel Jalil, Mariam Hantash, et al.
Publicado: (2023)

Evaluation of Therapeutic Vancomycin Monitoring in Taiwan
por: Chen, Tzu-Ting, et al.
Publicado: (2022)

P30 Evaluating vancomycin continuous infusion protocol compliance and gauging therapeutic target attainment in neonates
por: Lewis, Francesca, et al.
Publicado: (2023)

1111. Therapeutic Drug Monitoring of Colistin in Cerebrospinal Fluid in the Treatment of Neurosurgical Meningitis caused by Pseudomonas aeruginosa and KPC-producing Enterobacterales
por: Yasmin, Mohamad, et al.
Publicado: (2021)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

1100. A Prospective Evaluation of Neurotoxicity Among Patients Receiving Dose-Optimized Cefepime or Meropenem With Concomitant Therapeutic Drug Monitoring
por: Smith, Brandon, et al.
Publicado: (2021)

1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center
por: Veena, Venugopalan, et al.
Publicado: (2021)

162. Assessment of Beta-lactam Allergies as Rationale for Receipt of Vancomycin for Surgical Prophylaxis
por: Tucker, Kendall J, et al.
Publicado: (2020)

597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy
por: Nakrani, Monark, et al.
Publicado: (2020)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lh3f9v1qekmavb96cn240g89qs